Daratumumab for refractory aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if daratumumab, a targeted antibody therapy, can help patients with aplastic anemia that hasn't improved after standard treatments. It's for adults who cannot or choose not to have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have aplastic anemia that hasn't gotten better after at least 6 months of standard treatments like cyclosporine and a TPO receptor agonist.
- Your hemoglobin is below 90 g/L or your platelet count is below 30,000 per microliter.
- You are 18 years or older.
- You have not had certain infections (like HIV, active hepatitis, or active tuberculosis) recently.
- You have not used CD38-targeted therapy before or other specific immune drugs in the last few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This Phase 1 study tests a targeted radioactive medicine made from daratumumab plus a radioactive payload, aiming to treat multiple myeloma that has come back or doesn’t respond to treatment. It’s designed mainly to check safety and how the treatment works in people who have had several prior therapies.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.